Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A major Dana-Farber study shows frailty — not just age — is a powerful predictor of survival in older adults with blood cancers. Analyzing over 1,000 patients across 10 years, researchers found frail patients had dramatically shorter survival than robust ones. Even a simple 4-meter walking test doubled the risk of death for the slowest walkers, suggesting quick frailty screenings could transform treatment planning.
A landmark study from Dana-Farber Cancer Institute found that frailty is both common and a stronger predictor of survival than age alone in older adults with leukemia, lymphoma, and multiple myeloma. Published in Haematologica, the study analyzed more than 1,000 patients evaluated through Dana-Farber's Older Adult Hematologic Malignancies (OHM) Program over 10 years, with a median patient age of 78.
Researchers used three validated geriatric tools — a cumulative deficit frailty index, a phenotypic frailty model, and a 4-meter walking-speed test — all of which consistently showed that frail and pre-frail patients faced significantly higher mortality than robust patients. Strikingly, about 90% of patients appeared relatively healthy by standard oncology measures (ECOG scale), yet 40–70% were classified as pre-frail or frail by geriatric tools, highlighting a major gap in conventional assessments.
By the Numbers:
Why it matters: Standard oncology tools miss a large portion of vulnerable older patients. Integrating frailty assessments into routine cancer care could help clinicians better tailor treatments — avoiding both overtreatment and undertreatment — and ultimately improve outcomes for this growing patient population.
